Servier’s VORANIGO® (vorasidenib) tablets receives FDA approval as first targeted therapy for Grade 2 IDH-mutant glioma
Improving the lives of our patients
We work tirelessly to deliver meaningful therapeutics for the patients we serve.
Servier’s VORANIGO® (vorasidenib) tablets receives FDA approval as first targeted therapy for Grade 2 IDH-mutant glioma
Boston Business Journal Names Servier Pharmaceuticals a Best Places to Work for the Fourth Consecutive Year
Servier Initiates Critical Dialogue on AYA Cancer Survivorship at ASCO 2024